Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

INTRODUCTION: Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR‐TKI) and those who are treatment naive, respectively....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Chahoud, Jad, Msaouel, Pavlos, Campbell, Matthew T., Bathala, Tharakeswara, Xiao, Lianchun, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Yogesh, Jonasch, Eric, Sharma, Padmanee, Tannir, Nizar M.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Genitourinary Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066696/
https://ncbi.nlm.nih.gov/pubmed/32162795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0372
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares